Antares Pharma (ATRS) Receiving Somewhat Favorable News Coverage, Analysis Finds

Media coverage about Antares Pharma (NASDAQ:ATRS) has been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Antares Pharma earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 45.9212234134532 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the news articles that may have impacted Accern Sentiment’s rankings:

Several research firms have issued reports on ATRS. BidaskClub lowered shares of Antares Pharma from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 23rd. ValuEngine raised shares of Antares Pharma from a “sell” rating to a “hold” rating in a research note on Friday, March 9th. Finally, HC Wainwright set a $4.00 price target on shares of Antares Pharma and gave the stock a “buy” rating in a research note on Tuesday, March 27th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and two have assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $3.86.

Shares of NASDAQ ATRS remained flat at $$2.91 on Thursday. 1,263,975 shares of the company’s stock were exchanged, compared to its average volume of 1,127,161. Antares Pharma has a fifty-two week low of $1.58 and a fifty-two week high of $4.09. The company has a market capitalization of $435.98 million, a P/E ratio of -26.45 and a beta of 0.21. The company has a quick ratio of 2.39, a current ratio of 2.94 and a debt-to-equity ratio of 0.88.

Antares Pharma (NASDAQ:ATRS) last announced its earnings results on Tuesday, May 8th. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.01). Antares Pharma had a negative net margin of 32.96% and a negative return on equity of 52.74%. The business had revenue of $12.70 million for the quarter, compared to the consensus estimate of $12.85 million. research analysts forecast that Antares Pharma will post -0.08 earnings per share for the current year.

In other news, Director Jacques Gonella sold 200,000 shares of the stock in a transaction that occurred on Friday, May 11th. The shares were sold at an average price of $2.42, for a total transaction of $484,000.00. Following the sale, the director now owns 11,686,413 shares in the company, valued at $28,281,119.46. The transaction was disclosed in a filing with the SEC, which is available at this link. In the last quarter, insiders have sold 1,835,550 shares of company stock worth $4,670,194. Corporate insiders own 12.20% of the company’s stock.

About Antares Pharma

Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Insider Buying and Selling by Quarter for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with's FREE daily email newsletter.

Leave a Reply